Sept 19 (Reuters) - Dimension Therapeutics Inc  DMTX.O  
    * Dimension Therapeutics - Dimension board determines 
proposal from Ultragenyx Pharmaceutical could reasonably be 
expected to lead to "superior proposal" 
    * Dimension Therapeutics -co's board has not determined 
ultragenyx's proposal in fact constitutes superior proposal 
under existing deal with Regenxbio 
    * Dimension Therapeutics Inc - board has not changed its 
recommendation in support of merger with Regenxbio 
 
Source text for Eikon:  ID:nGNXOEILNa  
Further company coverage:  DMTX.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))